Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931083 | 0.90 | MEN1 (0.61) | THRBMAPTMEN1KMT2APOLB | |
| SCHEMBL2937117 | 0.90 | THRB (0.62) | THRBMAPTMEN1KMT2APOLB | |
| SCHEMBL2937575 | 0.86 | TP53 (0.61) | THRBMAPTPOLBTP53 | |
| SCHEMBL2935721 | 0.86 | TP53 (0.51) | THRBMAPTMEN1KMT2APOLB | |
| SCHEMBL2936544 | 0.84 | CHRM1 (0.44) | THRBMAPTMEN1KMT2APOLB | |
| SCHEMBL2930484 | 0.83 | MEN1 (0.49) | THRBMAPTMEN1KMT2APOLB | |
| SCHEMBL2937713 | 0.81 | CHRM1 (0.54) | THRBMAPTMEN1KMT2APOLB | |
| SCHEMBL2936547 | 0.79 | P2RX3 (0.57) | MAPTKMT2AP2RX3TP53 | |
| SCHEMBL2937266 | 0.78 | ALDH1A1 (0.53) | MAPTTP53GAA | |
| SCHEMBL2937566 | 0.78 | LMNA (0.61) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730135-B1 | QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) | US OF AMERICA REPRESENTED BY T (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7776883-B2 | Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2007-09-20 | — | — | US | disclosed |
| EP-1730135-A1 | QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087759-A1 | QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | QTRT1, QTRT2, CTCF | THRB 4067/4885MAPT 1583/4885MEN1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.